Contacter le RP

Pour utiliser cette fonctionnalité, vous devez bénéficier d'un compte Babbler.

arrow_back

Babbler permet aux journalistes et communicants de collaborer plus simplement.

En vous connectant, vous pourrez accéder gratuitement aux espaces presse des centaines d'entreprises de vos secteurs qui sont sur Babbler, entrer en contact direct avec leurs équipes RP mais aussi y partager vos prochains sujets !

Leurs espaces presse sont sur Babbler :

Vous êtes à 1 clic de l'inscription !

Précédent

Content de vous revoir !

Communiqué de presse

Liver Fibrosis Treatment Market Growth, Size, Outlook and Analysis, 2018–2026
timer minutes de lecture minute de lecture

Copier le lien
The global liver fibrosis treatment market size is expected to witness a CAGR of 10.8% over the forecast period (2018–2026) reaching a value of US$ 28.1 billion in 2026.

Cliquez sur l'image pour obtenir le format original

The Global Liver Fibrosis Treatment Market, segmented by Treatment Type (Peroxisome Proliferator-activated Receptors (PPAR)-alpha agonist, ACE Inhibitors, Hepatotropic Drug, and Others), by Condition (Chronic Liver Diseases, Hepatitis C, and Nonalcoholic Steatohepatitis), by End User (Hospitals, Specialty Clinics, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa) is projected to exhibit a CAGR of 10.8% over the forecast period (2018 - 2026),

Increasing number of clinical trials by key players focused on development of an efficient treatment option for liver fibrosis is expected to drive the growth of the liver fibrosis treatment market in near future.

Download PDF Brochure of Research Report @ https://www.coherentmarketinsights.com/insight/request-pdf/2320

In October 2010, FibroGen, Inc. initiated phase II clinical study of FG-3019: a human monoclonal antibody against the Connective Tissue Growth Factor (CTGF) to compare the efficacy in reversing the effects of liver fibrosis caused by chronic infection with hepatitis B virus (HBV).

In February 2018, Intercept Pharmaceuticals, Inc. initiated phase III trial of REVERSE trial (Randomized Phase 3 Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects with Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis). This randomized phase III study will evaluate the efficacy and safety of obeticholic acid in NASH patients with a biopsy-confirmed diagnosis of cirrhosis.

Browse 24 Market Data Tables and 28 Figures spread through 168 Pages and in-depth TOC on ‘Liver Fibrosis Treatment Market, by Treatment Type (Peroxisome Proliferator-activated Receptors (PPAR)-alpha agonist, ACE Inhibitors, Hepatotropic Drug, and Others), by Condition (Chronic Liver Diseases, Hepatitis C, and Nonalcoholic Steatohepatitis), by End User (Hospitals, Specialty Clinics, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa) - Global Forecast to 2026’

Furthermore, growing research collaboration among the key players to develop novel treatment regime combined with regulatory approval of underline drugs for treatment of liver fibrosis is expected to drive the market growth in near future.

For instance, in April 2017, Bristol-Myers Squibb Company and Nordic Bioscience signed a collaboration agreement for development of biomarker technology to potentially diagnose and monitor fibrosis disease including Non-alcoholic steatohepatitis (NASH). This collaboration will help patients to efficiently diagnose and monitor fibrosis disease.

In February 2018, the U.S. Food and Drug Administration (FDA) approved Vertex Pharmaceuticals’ SYMDEKO (tezacaftor/ivacaftor and ivacaftor) for the treatment of cystic fibrosis (CF) in people age 12 and older with certain mutations.

Request For Customization of Research Report @ https://www.coherentmarketinsights.com/insight/request-customization/2320

Key Takeaways of the Liver Fibrosis Treatment Market:

  • The global liver fibrosis treatment market is expected to grow at 10.8% CAGR over the forecast period, owing to increasing prevalence of risk factors affecting liver fibrosis, worldwide.
  • Among treatment type, hepatotropic drug accounted for significant market share in liver fibrosis treatment market, as it enables safe and efficient treatment for reducing fibrosis in patients.
  • Among end users, hospitals segment is expected to account for major market share during the forecast period, as hospital offer primary treatment option for patient suffering with liver fibrosis.
  • Some of the major players operating in the global liver fibrosis treatment market include Gilead Sciences, Inc., Merck & Co., Inc., Bristol-Myers Squibb, Johnson and Johnson, Novartis AG, Vertex Pharmaceuticals Incorporated, Pfizer Inc., FibroGen, Inc., and Pharmaxis Limited.

Browse Full Report: https://www.coherentmarketinsights.com/market-insight/liver-fibrosis-treatment-market-2320

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah

Coherent Market Insights

1001 4th Ave, 

#3200 

Seattle, WA 98154

Tel: +1-206-701-6702

Email: sales@coherentmarketinsights.com

Visit our news Website: https://www.coherentwire.com


Autres actualités de la marque

inscrit avec succès

Félicitations, vous êtes inscrit sur BABBLER !

Pour découvrir dès maintenant toutes les actualités qui vous attendent sur Babbler, consultez votre newsfeed !

Vos domaines ont été préselectionnés. Vous pouvez les compléter en cliquant ici